SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Kite Pharma, Inc. (KITE)
NEW YORK, May 8, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Kite Pharma, Inc. ("Kite" or the "Company") (NASDAQ: KITE). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/kite.
The investigation concerns whether Kite and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On May 8, 2017, Kite revealed that a cancer patient had died in April 2017 from brain swelling following treatment with its CAR-T therapy KTE-C19. Following this news, Kite stock has dropped as much as $11.54, or 14.11%, during intraday trading on May 8, 2017.
If you are aware of any facts relating to this investigation, or purchased shares of Kite, you can assist this investigation by visiting the firm's site: www.bgandg.com/kite. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article